AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04235998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Systematic lung ultrasound
Description: Patients will undergo a systematic lung ultrasound including review of:~* Sonographic characteristic of effusion~* Parietal, diaphragmatic and visceral pleura~* Pleural nodules~* Lung parenchyma~* Extra pulmonary findings: Hepatic pathology, enlarged lymph nodes of the neck and a cardiac assessment.
Study NCT01523002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol and pyronaridine-artesunate
Description: On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Day 10, a 100 mg dose of metoprolol will be coadministered with pyronaridine-artesunate at the above dose.~On Days 98 - 100, subjects will receive pyronaridine-artesunate once daily at the same dose described above. Followed by a 40 day follow-up period.
Study NCT01523002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyronaridine-artesunate
Description: On Days 1 to 3, subjects will receive 3 days of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Days 61 to 63, subjects will be redosed with a 3 day course of pyronaridine-artesunate at the above dose.~Followed by a 40 day follow-up period.
Study NCT05741177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: lung ultrasound score
Study NCT03280381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nifty feeding cup
Description: The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.
Study NCT03280381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Generic medicine cup
Description: The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
Study NCT00491400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: 140 mg/day for 8 weeks
Study NCT00491400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 20 mg/day for 8 weeks
Study NCT01850342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periurethral injection of fat micrograft enriched with ADRC
Description: Subjects will undergo liposuction under local anesthesia. One part of lipoaspirate will be processed to isolate and concentrate ADRCs. Another part of lipoaspirate will be washed and homogenized to prepare fat tissue micrograft. After that fat tissue micrograft will be mixed with ADRC. Autologous fat micrograft enriched with ADRC will be injected at the bulbomembranous region of urethra circle-wise under endoscopic vision.
Study NCT02078518 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Study NCT02177292 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
Study NCT00701259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 15 mg once per day for 14 days
Study NCT00701259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30 mg once per day for 14 days
Study NCT00701259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00201045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician/Pharmacist Collaborative Teams
Description: The patient's physician collaborates with a clinical pharmacist to improve management of hypertension
Study NCT01672684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: support group therapy
Description: Complete at-home group video calling support sessions
Study NCT01672684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive an educational workbook journal
Study NCT01698541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tested generic
Study NCT01698541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tested generic
Study NCT01698541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Original formulation used as comparator
Study NCT01698541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Original formulation used as comparator
Study NCT01503450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine OD Tablets 5 mg
Description: Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
Study NCT01503450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine OD Tablets 5 mg
Description: Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
Study NCT01378884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Patient to receive treatment with Domperidone
Study NCT03195998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TcB Measurement
Description: TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.
Study NCT02039401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202
Study NCT03353285 — intervention group
Intervention type: PROCEDURE
Intervention: intracytoplasmic sperm injection (ICSI)
Description: All eggs will be fertilized by ICSI
Study NCT05013398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Together Webinar Programme
Description: The TTP-Webinar consists of six hour-long sessions. Each session focuses on psychoeducation and self-management strategies for supporting veteran mental health difficulties as well as self-management tools to enhance partners' own wellbeing.~The TTP-Webinar treatment protocol incorporates a range of techniques used in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), Compassion Focused Therapy (CFT), and Acceptance and Commitment Therapy (ACT).
Study NCT04150016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical procedure that improves blood flow to your heart.PCI requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into your coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.
Study NCT04150016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical procedure that improves blood flow to your heart.PCI requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into your coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.
Study NCT00407732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychosocial intervention
Description: motivational enhancing case management intervention
Study NCT03439670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vamorolone
Description: Oral administration of 6.0 mg/kg/day for 20 weeks.
Study NCT03439670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vamorolone
Description: Oral administration of 6.0 mg/kg/day for 20 weeks.
Study NCT03192943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified dose on specified days
Study NCT02536846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
Study NCT04194645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 tablet
Description: BI 474121 tablet
Study NCT05141656 — intervention group
Intervention type: OTHER
Intervention: No intervention will be considered in this study.
Description: No intervention will be considered in this study.
Study NCT03192943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day
Study NCT02283047 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIET
Description: Lifestyle intervention through hypocaloric diet
Study NCT02283047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIET & MODERATE CONTINUOUS TRAINING
Description: Lifestyle intervention through hypocaloric diet and exercise at moderate intensity (60-80%peakHR) continuous mode, and high volume (45 min).
Study NCT02283047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIET & HIGH VOLUME HIIT
Description: Lifestyle intervention through hypocaloric diet and exercise at high intensity (80-95%peakHR) interval mode, and high volume (45 min).
Study NCT02283047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIET & LOW VOLUME HIIT
Description: Lifestyle intervention through diet and exercise at high intensity (80-95%peakHR) interval mode, and low volume (20 min).
Study NCT01355445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine, Irinotecan
Description: * D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days
Study NCT01355445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine, Irinotecan, Temozolomide
Description: * D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience > grade 3 toxicity of any kind)~* D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days
Study NCT01487460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAP311
Study NCT01487460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP311
Study NCT02753998 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Additional angioplasty with paclitaxel-coated balloon
Description: Additional angioplasty with paclitaxel-coated balloon after conventional angioplasty
Study NCT02753998 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Additional angioplasty with placebo balloon
Description: Additional angioplasty with placebo balloon after conventional angioplasty
Study NCT02753998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional angioplasty
Study NCT02753998 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional angioplasty
Study NCT00729794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone
Description: Combination Treatment~Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR
Study NCT00729794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard CPR Protocol with Epinephrine and two Placebos
Description: Patients receive advanced life support according to the Guidelines for Resuscitation 2005
Study NCT03315377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lunate-Capitate Fusion (LCF)
Description: Operation with lunate-capitate-fusion (LCF)
Study NCT03315377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four Corner Fusion (4CF)
Description: Operation with four-corner-fusion (4CF)
Study NCT04732104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: intranasal spray anesthesia will be administered for achieving pulpal local anesthesia of maxillary anterior and premolar teeth. Xylometazoline OTC decongestant will be used to prolong the duration of anesthesia
Study NCT04732104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: injectable local anesthesia will be administered to achieve pulpal local anesthesia of maxillary anterior and premolar teeth
Study NCT02519868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical block
Description: Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography
Study NCT02519868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chemical block
Description: Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
Study NCT02915185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: strength training intervention
Description: The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
Study NCT02915185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
Study NCT01164553 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Inactivated Influenza Vaccine
Description: Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
Study NCT01164553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza Vaccine
Description: Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
Study NCT01670565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
Study NCT01670565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at \<2,000 mg/day for \<3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
Study NCT01947920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl, 50 mg
Description: 50-mg overencapsulated tablet for oral administration
Study NCT02915211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Keyo
Description: Keyo is a Food for Special Medical Purposes (FSMP) and is intended for use in the KD. It has a fat to protein and carbohydrate ratio of 3 to 1. This makes it appropriate for inclusion in all versions of the KD - classical, MCT, MAD and LGI. Keyo has been designed as a nutritionally complete, ready to use, pleasant tasting and versatile medical food for use in a KD.
Study NCT02291406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal hysterectomy
Description: Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
Study NCT02291406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot assisted laparoscopic hysterectomy
Description: Robotic assisted total laparoscopic hysterectomy.
Study NCT01670565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at \<2,000 mg/day for \<3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
Study NCT01670565 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Infusion of normal saline
Study NCT03873506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transplantation of hUC-MSCs
Description: Human umbilical cord-derived mesenchymal stem cells had given to preterm infants through intravenous infusion.
Study NCT03476161 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive. 4069-6103 / 4069-6114 / 4069-6203 / 4069-6214
Description: One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
Study NCT05569343 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention
Study NCT01683669 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Noisy-PSV 1
Description: Noisy-PSV 1: different levels of variable pressure support (PS) will be randomized: a) PS variability equal to 0%, b) PS variability equal to 45%, c) PS variability equal to 90%.
Study NCT01683669 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Noisy-PSV 2
Description: Noisy-PSV 2 : different levels of variable Pressure Support (PS) will be randomized: a) PS equal to Baseline and variability 0%; b) PS equal to Baseline and variability set in order achieve an increase or decrease of pressure of 5 cmH2O; c) PS equal to Baseline - 5 cmH2O and variability 0%; d) PS equal to Baseline - 5 cmH2O and set in order achieve an increase or decrease of pressure of 5 cmH2O.
Study NCT02860949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL
Study NCT01947920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Size-matching capsules containing an appropriate inactive excipient
Study NCT02860949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL